ArticleVaccine2020
Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06536855 (Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
Who cites it
40 citing papers in PubMed.
- Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.Health science reports · 2026Review
- Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low- and middle-income countries: a modelling study.BMJ global health · 2026Article
- Potential Impact of Catch-Up HPV Vaccination on HPV Prevalence and Cervical Cancer Incidence Among Women Living With HIV in South Africa: Results From Two Mathematical Models.Journal of the International AIDS Society · 2026Article
- Determinants of human papillomavirus vaccine non-uptake among adolescent girls in Ethiopia: evidence from National Immunization Survey.BMJ open · 2026Article
- Geographic and demographic patterns of cervical cancer in Africa using GLOBOCAN 2022.BMC cancer · 2026Article
- Knowledge, attitudes, and practices of cervical cancer preventive services among mothers living with HIV in Lagos, Nigeria: a cross-sectional study.BMC public health · 2026Article
- Article
- Treatment response after chemoradiation with an external beam radiation therapy boost in cervical cancer patients in Rwanda.The oncologist · 2025Article
- Global disparities in gynecologic cancer outcomes: A call for action.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Review
- Prevalence of Human Papillomavirus and Genotype Correlation with Cervical Lesions at the University Teaching Hospital of Kigali.The American journal of tropical medicine and hygiene · 2025Article
- Quantifying the impact of introducing HPV vaccines in 2006 on 25-29-year-old cervical cancer incidence in 2022.JNCI cancer spectrum · 2025Article
- HPV Vaccine Delivery Strategies to Reach Out-of-School Girls in Low- and Middle-Income Countries: A Narrative Review.Vaccines · 2025Review
- Review
- The Global Fund, Cervical Cancer, and HPV infections: what can low- and middle-income countries do to accelerate progress by 2030?EClinicalMedicine · 2025Review
- Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples.Journal of clinical microbiology · 2025Article
- Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment.Frontiers in public health · 2025Article
- Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings.Journal of the National Cancer Institute. Monographs · 2024Article
- The acceptance of COVID-19 vaccines in Rwanda: a cross-sectional study.BMC public health · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn 2011, Rwanda became the first African nation to implement a national human papillomavirus (HPV) vaccination program, conceived to protect girls aged <15 years (i.e. born ≥1997). After an initial school-grade-targeted catch-up campaign, there was a transition to routine vaccination of 12 year-olds only. We aimed to produce population-level vaccine coverage estimates.
methodsThe Rwandan Expanded Program on Immunization (EPI) collected data on number of eligible girls and HPV vaccines delivered, stratified by calendar year (2011-2018), girl's age, district and vaccination round. HPV vaccine coverage was estimated by birth cohort (reconstituted using calendar year and age), as a proportion of (1) eligible target, and (2) the 2012 Rwandan census population.
results1,156,863 girls received first dose of HPV vaccine between 2011 and 2018, corresponding to 98% of the eligible target. Median vaccination age was 15 years (interquartile range [IQR] 13-16) in 2011-2013 (school grade-targeted catch-up), 13 years (IQR 12-14) in 2014 (transition) and 12 years in 2015-2018 (routine). Population-level coverage versus the census increased from 10 to 40% for girls born in 1993-1995 (median vaccination age = 17 years) to 50-65% for 1996-2000 birth cohorts (14 years), and 80-90% for 2001-2006 birth cohorts (12 years). Coverage trends were similar across provinces and in the capital, Kigali. Second and third round coverage suggested most vaccinated girls completed their recommended dosing regimen (which reduced from 3 to 2 doses in 2015).
conclusionsBirth cohorts provide a clear picture of population-level HPV vaccine coverage after a pragmatic catch-up campaign, particularly in Rwanda where eligible school grades included wide age ranges. Whilst the catch-up campaign resulted in some coverage gaps in out-of-school teenagers, coverage remains high in cohorts routinely targeted as 12 year-olds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.